3bkc: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Seed}}
[[Image:3bkc.png|left|200px]]


<!--
==Crystal structure of anti-amyloid beta FAB WO2 (P21, FormB)==
The line below this paragraph, containing "STRUCTURE_3bkc", creates the "Structure Box" on the page.
<StructureSection load='3bkc' size='340' side='right'caption='[[3bkc]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
You may change the PDB parameter (which sets the PDB file loaded into the applet)  
== Structural highlights ==
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
<table><tr><td colspan='2'>[[3bkc]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BKC OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3BKC FirstGlance]. <br>
or leave the SCENE parameter empty for the default display.
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.9&#8491;</td></tr>
-->
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>
{{STRUCTURE_3bkc|  PDB=3bkc  |  SCENE=  }}
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3bkc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3bkc OCA], [https://pdbe.org/3bkc PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3bkc RCSB], [https://www.ebi.ac.uk/pdbsum/3bkc PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3bkc ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/A2NHM3_MOUSE A2NHM3_MOUSE]
== Evolutionary Conservation ==
[[Image:Consurf_key_small.gif|200px|right]]
Check<jmol>
  <jmolCheckbox>
    <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/bk/3bkc_consurf.spt"</scriptWhenChecked>
    <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked>
    <text>to colour the structure by Evolutionary Conservation</text>
  </jmolCheckbox>
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3bkc ConSurf].
<div style="clear:both"></div>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Alzheimer's disease (AD) is the most common form of dementia. Amyloid-beta (A beta) peptide, generated by proteolytic cleavage of the amyloid precursor protein, is central to AD pathogenesis. Most pharmaceutical activity in AD research has focused on A beta, its generation and clearance from the brain. In particular, there is much interest in immunotherapy approaches with a number of anti-A beta antibodies in clinical trials. We have developed a monoclonal antibody, called WO2, which recognises the A beta peptide. To this end, we have determined the three-dimensional structure, to near atomic resolution, of both the antibody and the complex with its antigen, the A beta peptide. The structures reveal the molecular basis for WO2 recognition and binding of A beta. The A beta peptide adopts an extended, coil-like conformation across its major immunodominant B-cell epitope between residues 2 and 8. We have also studied the antibody-bound A beta peptide in the presence of metals known to affect its aggregation state and show that WO2 inhibits these interactions. Thus, antibodies that target the N-terminal region of A beta, such as WO2, hold promise for therapeutic development.


===Crystal structure of anti-amyloid beta FAB WO2 (P21, FormB)===
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope.,Miles LA, Wun KS, Crespi GA, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW J Mol Biol. 2008 Mar 14;377(1):181-92. Epub 2008 Jan 30. PMID:18237744<ref>PMID:18237744</ref>


From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 3bkc" style="background-color:#fffaf0;"></div>


<!--
==See Also==
The line below this paragraph, {{ABSTRACT_PUBMED_18237744}}, adds the Publication Abstract to the page
*[[Antibody 3D structures|Antibody 3D structures]]
(as it appears on PubMed at http://www.pubmed.gov), where 18237744 is the PubMed ID number.
*[[Sandbox 20009|Sandbox 20009]]
-->
*[[3D structures of non-human antibody|3D structures of non-human antibody]]
{{ABSTRACT_PUBMED_18237744}}
== References ==
 
<references/>
==About this Structure==
__TOC__
3BKC is a [[Protein complex]] structure of sequences from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3BKC OCA].
</StructureSection>
 
[[Category: Large Structures]]
==Reference==
Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope., Miles LA, Wun KS, Crespi GA, Fodero-Tavoletti MT, Galatis D, Bagley CJ, Beyreuther K, Masters CL, Cappai R, McKinstry WJ, Barnham KJ, Parker MW, J Mol Biol. 2008 Mar 14;377(1):181-92. Epub 2008 Jan 30. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/18237744 18237744]
[[Category: Mus musculus]]
[[Category: Mus musculus]]
[[Category: Protein complex]]
[[Category: Bageley CJ]]
[[Category: Bageley, C J.]]
[[Category: Barnham KJ]]
[[Category: Barnham, K J.]]
[[Category: Beyreuther K]]
[[Category: Beyreuther, K.]]
[[Category: Cappai R]]
[[Category: Cappai, R.]]
[[Category: Crespi GA]]
[[Category: Crespi, G A.]]
[[Category: Fodero-Tavoletti M]]
[[Category: Fodero-Tavoletti, M.]]
[[Category: Galatis D]]
[[Category: Galatis, D.]]
[[Category: Masters CL]]
[[Category: Masters, C L.]]
[[Category: McKinstry WJ]]
[[Category: McKinstry, W J.]]
[[Category: Miles LA]]
[[Category: Miles, L A.]]
[[Category: Parker MW]]
[[Category: Parker, M W.]]
[[Category: Wun KS]]
[[Category: Wun, K S.]]
[[Category: Abeta]]
[[Category: Alzheimer's disease]]
[[Category: Amyloid beta peptide]]
[[Category: App]]
[[Category: Fab]]
[[Category: Immune system]]
[[Category: Immunotherapy]]
[[Category: Wo2]]
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 11:08:42 2008''
Retrieved from "https://proteopedia.org/3bkc"